Anti-VEGF (vascular endothelial growth factor) therapy is a targeted ocular treatment used to manage retinal vascular diseases by inhibiting VEGF, a protein responsible for abnormal blood vessel growth and fluid leakage in the retina. This therapy is primarily used to treat conditions such as age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion (RVO), and myopic choroidal neovascularisation (mCNV).
Anti-VEGF agents neutralise VEGF activity through direct intraocular injection, reducing retinal swelling, preserving vision, and preventing disease progression. As of 2020, AMD affected over 200 million individuals globally, with projections estimating a rise to 288 million by 2040. The development of anti-VEGF therapy marked a critical advancement in ophthalmology. Dr. Napoleone Ferrara’s discovery of VEGF and its inhibitors enabled the creation of key drugs such as ranibizumab (Lucentis) and bevacizumab (Avastin).
This article presents a detailed overview of anti-VEGF therapy, beginning with its definition and mechanism of action, followed by the eye conditions it treats, how the therapy works, pre-treatment preparations, procedural steps, post-treatment care, the medications used, clinical effectiveness across conditions, cost variations and biosimilar options, leading therapy centers, potential risks and side effects, and concluding with alternative treatment options.
It provides a comprehensive and clinically accurate resource on anti-VEGF therapy to patients seeking informed treatment decisions, caregivers, ophthalmologists, clinical researchers, and healthcare professionals involved in retinal disease management.
What is Anti-VEGF Therapy?
Anti-VEGF therapy is a targeted ocular treatment used to block the activity of Vascular Endothelial Growth Factor (VEGF), a protein that stimulates the formation of new blood vessels, a process known as angiogenesis. In retinal diseases, VEGF levels become abnormally elevated, leading to the growth of fragile and leaky blood vessels that impair vision.
Anti-VEGF drugs inhibit this process by binding directly to VEGF molecules, preventing them from interacting with VEGF receptors on retinal blood vessels. This inhibition blocks the angiogenic signalling cascade, thereby halting abnormal vessel growth, reducing fluid leakage, and preserving retinal structure.
The therapy is administered via intraocular injections and is a cornerstone treatment for conditions such as age-related macular degeneration (AMD) and diabetic retinopathy.
What Eye Conditions can be Treated with Anti-VEGF Therapy?
Anti-VEGF therapy treats several retinal diseases characterised by abnormal blood vessel growth and fluid accumulation. The primary conditions include Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularisation (mCNV). Each condition is described below, along with how anti-VEGF therapy contributes to its management:
1. Age-Related Macular Degeneration (AMD):
AMD involves the growth of abnormal blood vessels beneath the macula, the central region of the retina responsible for sharp vision. These vessels leak fluid or blood, causing central vision loss. Anti-VEGF therapy blocks VEGF activity, reducing neovascularisation and fluid leakage, thereby slowing disease progression and preserving vision.
2. Diabetic Retinopathy:
Diabetic retinopathy results from chronic hyperglycemia damaging retinal capillaries, leading to leakage, ischemia, and eventually, the growth of abnormal vessels. Anti-VEGF therapy reduces retinal swelling, inhibits neovascularisation, and stabilises or improves visual outcomes in both non-proliferative and proliferative forms of the disease.
3. Retinal Vein Occlusion (RVO):
RVO is caused by retinal vein blockage, leading to increased venous pressure, fluid leakage, and macular oedema. Anti-VEGF therapy reduces vascular permeability, controls oedema, and improves visual acuity by stabilising the retinal microenvironment.
4. Myopic Choroidal Neovascularisation (mCNV):
mCNV occurs in individuals with high myopia, where degenerative changes in the eye wall promote the formation of abnormal blood vessels under the retina. Anti-VEGF injections suppress neovascular growth and reduce fluid accumulation, effectively controlling disease activity and maintaining central vision.
While the above-listed conditions are the most common FDA-approved or guideline-recommended uses, anti-VEGF therapy is also employed off-label in conditions such as polypoidal choroidal vasculopathy (PCV), central serous chorioretinopathy (CSCR), radiation retinopathy, neovascular glaucoma, and retinopathy of prematurity (ROP), based on disease severity and individualised clinical assessment.
How Does Anti-VEGF Therapy Work?
Anti-VEGF therapy works by neutralising vascular endothelial growth factor (VEGF), a protein that stimulates the formation of abnormal blood vessels in the retina. In retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO), VEGF levels increase abnormally due to hypoxia or tissue injury.
This overexpression triggers neovascularisation and vascular leakage, which leads to retinal swelling and vision loss. Anti-VEGF drugs block this process by binding to VEGF and preventing it from activating its receptors on retinal blood vessels.
Before the Treatment
Anti-VEGF treatment begins with a thorough diagnostic assessment. Patients undergo comprehensive eye examinations, including optical coherence tomography (OCT) and fluorescein angiography, to evaluate retinal thickness and detect vascular leakage. These imaging tests confirm the indication for anti-VEGF therapy and establish baseline retinal function.
Prior to the injection, the ophthalmologist explains the procedure, frequency of treatment, expected outcomes, and potential side effects. Informed consent is obtained. The eye is then disinfected using a povidone-iodine solution to minimise infection risk. Topical anaesthetic drops are administered to numb the eye and enhance patient comfort.
During the Treatment
The injection procedure is performed under sterile conditions in a clinical setting. Once anaesthesia takes effect, a fine-gauge needle is used to inject the anti-VEGF drug directly into the vitreous humour, the gel-like substance in the centre of the eye. The entire procedure typically takes less than 10 minutes.
Patients may experience slight pressure during the injection, but significant pain is uncommon due to effective topical anaesthesia. The injection site is examined immediately post-procedure to detect any complications such as subconjunctival haemorrhage or anterior inflammation.
After the Treatment
Post-injection care focuses on monitoring for side effects and preparing for follow-up. Patients are advised to avoid eye rubbing, swimming, and strenuous activities for at least 24 hours. Temporary redness or irritation may occur, but usually resolves within 48 hours.
Scheduled follow-up appointments are critical to assess treatment response using repeat imaging. Based on clinical findings, the ophthalmologist determines the timing of subsequent injections, typically every 4 to 8 weeks. Ongoing monitoring ensures early detection of complications such as endophthalmitis, intraocular pressure elevation, or retinal detachment.
With consistent administration, anti-VEGF therapy reduces retinal fluid, stabilises vision, and often improves visual acuity. It remains the frontline intervention for multiple vision-threatening retinal diseases.
What Medications are Required for Anti-VEGF Therapy?
Anti-VEGF therapy is aided by four primary medications: ranibizumab (Lucentis), aflibercept (Eylea), bevacizumab (Avastin), and brolucizumab (Beovu). Each drug neutralises VEGF activity but differs in structure, indication, dosing frequency, efficacy, and cost, and has been explained below:
1. Ranibizumab (Lucentis)
Ranibizumab is a monoclonal antibody fragment specifically engineered for intraocular injection. It is FDA-approved for multiple retinal conditions, including neovascular AMD, DME, and RVO. The standard administration protocol involves monthly injections, with some patients transitioning to individualised regimens such as treat-and-extend based on clinical response.
2. Aflibercept (Eylea)
Aflibercept is a recombinant fusion protein that binds to VEGF-A, VEGF-B, and placental growth factor (PIGF). It is approved for the same indications as ranibizumab. Following an initial loading phase of monthly injections, aflibercept allows for dosing every 8 weeks, providing extended treatment intervals in responsive cases.
3. Bevacizumab (Avastin)
Bevacizumab is a full-length monoclonal antibody originally developed for cancer therapy. Although not FDA-approved for ocular use, it is widely employed off-label for retinal conditions. The typical dosing schedule consists of injections every 4 weeks. Bevacizumab requires compounding from larger vials into aliquots suitable for intraocular administration.
4. Brolucizumab (Beovu)
Brolucizumab is a single-chain antibody fragment approved for the treatment of neovascular AMD. Its compact molecular structure permits higher molar dosing in smaller injection volumes. The therapy begins with three monthly loading doses, followed by maintenance injections at intervals of up to 12 weeks, depending on patient response.
The final choice of anti-VEGF medication depends on factors such as disease severity, patient preferences, and cost considerations. Physicians work with patients to customise treatment plans, balancing benefits and potential risks.
How Effective is Anti-VEGF Therapy?
Anti-VEGF therapy is highly effective in managing retinal vascular diseases. It prevents vision loss in most patients and improves visual acuity in specific cases, depending on the underlying condition and treatment adherence.
Anti-VEGF therapy prevents vision loss in 90–95% of patients with wet AMD. Approximately 30–40% of treated individuals gain three or more lines of vision on the Snellen chart. Monthly or bi-monthly dosing maintains disease suppression. The MARINA and ANCHOR trials established ranibizumab’s superiority over placebo in visual gains and anatomical improvement. According to the American Academy of Ophthalmology (AAO), ranibizumab, aflibercept, and off-label bevacizumab offer comparable effectiveness in wet AMD over two years.
Patients with DME experience a 50% reduction in central macular thickness and an average 10-15 letter improvement in visual acuity after 12 months of treatment. Early initiation of therapy leads to better structural and functional outcomes. The VIVID and VISTA trials confirmed aflibercept’s benefit in DME over laser therapy.
In branch and central RVO, anti-VEGF injections reduce macular oedema and improve vision in 60-70% of cases. The BRAVO and CRUISE trials reported visual gains of 15 or more letters in approximately 60% of patients after six months of monthly injections. Response is typically observed within the first three months of treatment.
Anti-VEGF agents induce regression of retinal neovascularisation in up to 70% of patients with non-proliferative or early proliferative diabetic retinopathy. The RISE and RIDE trials demonstrated a 75–80% reduction in the risk of progression to proliferative stages with regular ranibizumab treatment. Anti-VEGF therapy reduces the need for pan-retinal laser photocoagulation in many cases.
Sustained efficacy depends on continued follow-up and treatment individualisation. After initial monthly loading doses, most patients transition to personalised regimens such as treat-and-extend or PRN (pro re nata) protocols. Typical maintenance intervals range from 4 to 12 weeks based on disease response. Ongoing monitoring through OCT imaging and visual acuity testing is critical to detect recurrence early. Discontinuation or non-compliance increases the risk of irreversible visual loss.
How much does Anti-VEGF Therapy Cost?
Anti-VEGF therapy in India is significantly more affordable than in Western countries, with per-injection costs ranging from ₹5,000 to ₹45,000 depending on the medication used. Below is a cost breakdown of the most popular medications:
- Ranibizumab (Lucentis): FDA-approved branded therapy priced between ₹25,000 and ₹45,000 per injection in India.
- Aflibercept (Eylea): FDA-approved branded therapy with similar pricing to ranibizumab, ranging from ₹25,000 to ₹45,000 per injection.
- Bevacizumab (Avastin): Off-label, repurposed cancer drug used widely due to affordability; costs ₹5,000 to ₹8,000 per injection. Accounts for 70-80% of anti-VEGF injections in India.
- Brolucizumab (Beovu): Newer FDA-approved therapy for AMD; priced at ₹27,000 to ₹35,000 per injection.
Indian pharmaceutical companies now produce biosimilar versions of ranibizumab, reducing costs by 30-40% compared to the imported originator products. Razumab, manufactured by Intas Pharmaceuticals, was India’s first biosimilar ranibizumab, which was approved in 2015. These domestically produced alternatives typically cost ₹15,000-20,000 per injection, positioning them between bevacizumab and imported branded options.
What are The Best Anti-VEGF Therapy Centres?
Eye7 Eye Hospitals is a leading institution in India offering structured, retina-focused care for patients undergoing anti-VEGF therapy. The hospital houses specialised retina clinics with high-resolution imaging platforms, including spectral-domain optical coherence tomography (SD-OCT), OCT angiography, and ultra-wide fundus imaging. These diagnostic tools support accurate disease staging and personalised treatment planning.
All major anti-VEGF agents, bevacizumab, ranibizumab, aflibercept, and biosimilar formulations, are available at Eye7 Eye Hospitals, allowing therapy selection based on clinical needs and financial considerations. The hospital offers bundled treatment packages that include consultation, imaging, and injection services. Pricing is standardised, and financial counsellors can assist with insurance coordination and payment planning.
Through integrated diagnostics, multi-drug access, and structured service delivery, Eye7 Eye Hospital is a comprehensive care centre for anti-VEGF therapy in India.
What are the Risks & Side Effects of Anti-VEGF Therapy?
Anti-VEGF therapy is generally well-tolerated, but like any intraocular procedure, it carries a defined set of risks ranging from mild, self-limiting side effects to rare but serious complications. The key risks are outlined below:
Common Side Effects:
Mild ocular side effects occur in approximately 5-10% of injections. These include:
- Subconjunctival haemorrhage (bloodshot appearance)
- Mild eye discomfort or pain
- Temporary floaters
These transient effects typically resolve within 24-48 hours without intervention.
Moderate Side Effects:
A small proportion of patients (1-2%) may experience:
- Anterior chamber inflammation
- Transient increases in intraocular pressure (IOP)
IOP spikes often normalise within one hour, but should be monitored in patients with glaucoma. Inflammation is generally managed with topical anti-inflammatory drops and resolves within 3-5 days.
Rare but Serious Risks:
Severe complications are rare, occurring in less than 0.1% of cases. These include:
- Endophthalmitis (intraocular infection)
- Retinal detachment
- Persistent vision loss
To minimise complications, a strict sterile technique is used during injection. Patients are advised to report symptoms such as increasing pain, vision changes, or severe redness. Adherence to post-injection care guidelines supports safe recovery.
What are the Alternatives to Anti-VEGF Therapy?
While anti-VEGF therapy remains the standard of care for retinal vascular diseases, several alternative treatments are available for patients who are non-responsive, intolerant, or require adjunctive therapy. These include laser procedures, corticosteroid-based therapies, photodynamic therapy, surgical interventions, and emerging treatments, each offering distinct mechanisms of action.
Each of them is briefly explained below, along with their clinical roles, target conditions, procedural context, and limitations.
1. Laser Photocoagulation:
Conventional laser photocoagulation treats diabetic retinopathy and branch retinal vein occlusion by applying focal burns to seal leaking microaneurysms and reduce retinal oxygen demand. Although effective in stabilising the disease, it results in permanent retinal scarring and is typically limited to non-central areas.
Focal laser therapy is also used for extrafoveal choroidal neovascularisation and achieves disease stabilisation in approximately 50% of cases. Newer targeting techniques have reduced collateral retinal damage and improved precision.
2. Corticosteroid Implants and Injections:
Intravitreal corticosteroids, such as dexamethasone implants, offer an alternative for patients with diabetic macular oedema or retinal vein occlusion who are suboptimal responders to anti-VEGF therapy. These agents reduce retinal inflammation and vascular permeability but increase the risk of elevated intraocular pressure and cataract progression.
3. Photodynamic Therapy (PDT):
Photodynamic therapy combines intravenous verteporfin (Visudyne) with low-energy laser activation to close abnormal choroidal vessels selectively. PDT is primarily indicated for polypoidal choroidal vasculopathy and chronic central serous chorioretinopathy. It generally requires 2-3 sessions and avoids the tissue damage associated with thermal lasers.
4. Surgical Interventions
Pars plana vitrectomy is indicated in advanced diabetic retinopathy cases complicated by vitreous haemorrhage or tractional retinal detachment. This approach is often used after anti-VEGF therapy has failed or as part of a combined treatment plan. Postoperative recovery includes 2-4 weeks of limited activity.
5. Emerging and Investigational Treatments: Research into sustained-release anti-VEGF implants, gene therapy, and combination approaches involving anti-angiogenic and anti-inflammatory agents is ongoing. These modalities aim to reduce injection frequency and improve long-term retinal stability.
Resources
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10300666/
- https://pubmed.ncbi.nlm.nih.gov/18568940/
- https://www.aao.org/eye-health/diseases/avastin-eylea-lucentis-difference